Genotype-phenotype correlation in Moroccan patients with primary congenital glaucoma.

J Glaucoma

*Service d'Ophtalmologie B, Hôpital des Spécialités, CHU Ibn Sina, Equipe de Recherche sur les Maladies Oculaires, Faculté des Médecine et de Pharmacie †Laboratoire de Biologie Générale et Zoologie-Equipe de Biologie des Organismes et des Populations, Université Mohammed V-Agdal, Faculté des Sciences ‡Institut National de la Recherche Agronomique, UR Biotechnologie, Rabat, Morocco.

Published: June 2015

Purpose: To investigate the genotype-phenotype correlation in a large cohort of Moroccan primary congenital glaucoma (PCG) in which CYP1B1 mutation spectrum was recently reported by our group.

Methods: This study included 94 patients from 84 unrelated Moroccan PCG families with or without CYP1B1 mutations. Clinical features, severity of the phenotype, and prognosis were mainly compared in patients with no CYP1B1 mutations, double CYP1B1 null alleles or nondouble null but other CYP1B1 mutations; most of them were hypomorphic mutations. Statistical analyses were performed using SAS and SPSS softwares. Significance was set at P<0.05.

Results: Mean of intraocular pressure, corneal diameter and number of surgery values and cup-to-disc ratios, and percentages of patients with bilateral PCG, eyes with severe opacities and severe phenotype, and those that needed >1 trabeculectomy were significantly higher in the CYP1B1 mutation carriers (n=51) than in the no CYP1B1 mutation group (n=43). The same results were observed when patients with double CYP1B1 null alleles (n=34) were compared with those with no CYP1B1 mutation. The comparison between the no CYP1B1 mutation patients and those with nondouble null but other CYP1B1 mutations (n=17) showed significant differences in the percentage of bilateral PCG and percentages of eyes with severe opacities and severe phenotype. When the double CYP1B1 null allele carriers were compared with the nondouble null but other CYP1B1 mutation group, only significant differences were observed in the mean number of surgery values. Multivariate analysis revealed that, after adjustment of the parameters that showed significant differences in univariate analyses, corneal diameter was the main factor explaining the severity of PCG only in the double CYP1B1 null allele carriers.

Conclusions: This is the first report of genotype-phenotype correlation in a large cohort of Moroccan PCG. Our results revealed that the worst phenotype and prognosis were observed in the double null CYP1B1 allele carriers followed by the nondouble null but other CYP1B1 mutations. This will contribute to the prediction of the prognosis of the disease.

Download full-text PDF

Source
http://dx.doi.org/10.1097/IJG.0b013e31829f99b7DOI Listing

Publication Analysis

Top Keywords

cyp1b1 mutation
24
cyp1b1 mutations
20
null cyp1b1
20
cyp1b1
16
double cyp1b1
16
cyp1b1 null
16
nondouble null
16
genotype-phenotype correlation
12
null
9
primary congenital
8

Similar Publications

Loss-of-function mutations in PARK7, encoding for DJ-1, can lead to early onset Parkinson's disease (PD). In mice, Park7 deletion leads to dopaminergic deficits during aging, and increased sensitivity to oxidative stress. However, the severity of the reported phenotypes varies.

View Article and Find Full Text PDF

Functional genomics of primary congenital glaucoma by pathway analysis and functional characterization of CYP1B1 mutations.

Vision Res

December 2024

Medical Biotechnology Laboratory, Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007, India. Electronic address:

CYP1B1 is the most common gene implicated in primary congenital glaucoma (PCG) - the most common form of childhood glaucoma. How CYP1B1 mutations cause PCG is not known. Understanding the mechanism of PCG caused by CYP1B1 mutations is crucial for disease management, therapeutics development, and potential prevention.

View Article and Find Full Text PDF

Background: Cytochromes P450 (CYPs) are heme-containing oxidoreductase enzymes with mono-oxygenase activity. Human CYPs catalyze the oxidation of a great variety of chemicals, including xenobiotics, steroid hormones, vitamins, bile acids, procarcinogens, and drugs.

Findings: In our review article, we discuss recent data evidencing that the same CYP isoform can be involved in both bioactivation and detoxification reactions and convert the same substrate to different products.

View Article and Find Full Text PDF

miRNA-148a-3p targets to regulate the lipid metabolism gene SOCS3 to reduce myocardial ischemia/reperfusion injury.

Minerva Cardiol Angiol

November 2024

Guangxi Key Laboratory of Basic Medical Research Support for Immune-related Diseases, Baise, Guangxi, China -

Background: Acute myocardial infarction (AMI) is a major cause of death in cardiovascular patients. SOCS3's protective role in cardiac I/R-I is being explored, and miRNAs, particularly miRNA-148a-3p, are suspected to target SOCS3. To elucidate the role of miRNA-148a-3p targeting lipid metabolism gene SOCS3 in cardiac ischemia-reperfusion injury (I/R-I) in rats.

View Article and Find Full Text PDF

CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer.

Drug Resist Updat

November 2024

Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou,  China; Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Hangzhou, China; Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Reproductive Health Research, Hangzhou, China. Electronic address:

Article Synopsis
  • Ovarian cancer, the deadliest gynecological cancer, faces major treatment obstacles, particularly with PARP inhibitors (PARPi) for BRCA1/2-mutated tumors, as resistance to these drugs is a significant challenge.
  • An experiment developed a PARPi-resistant cell line (A2780-OlaR), revealing increased levels of CYP1B1, and demonstrated that manipulating its expression affected responses to Olaparib, the PARP inhibitor.
  • The study concludes that CYP1B1 plays a crucial role in PARPi resistance, showing how chromatin accessibility impacts drug effectiveness and suggesting new strategies to fight ovarian cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!